Adalimumab biosimilar (Sinomab Bioscience/Shanghai Biomabs)

N/A

Report date: 2022/03/14 10:37:59

Base Information

Drug NameAdalimumab biosimilar (Sinomab Bioscience/Shanghai Biomabs)
Drug Alias NameCMAB815注射液CMAB-815
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusIND
Highest Status in ChinaIND
Originator CompaniesShanghai Biomabs Pharmaceuticals Co LtdSinomab Bioscience Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Biomabs Pharmaceuticals Co Ltd
Inactive CompaniesN/A
Active IndicationsArthritis, Rheumatoid
Inactive IndicationsN/A

Other Information

ATC CodeL04AB04
Related LinksN/A